BACKGROUND: Data on routine systemic treatment of @entity1 with @entity43 are currently available only to a limited degree. The alkylating agent @entity21193 is approved in oral (p.o.) and intravenous (i.v.) form for the treatment of @entity43 . The present non-interventional study analyzed the clinical use of @entity21193 in Germany, evaluating the mode of application, @entity137 , and response and survival rate. @entity1 AND METHODS: Two hundred and forty-eight @entity43 @entity1 in 57 Centers, who received @entity21193 mainly either i.v. (5,000-8,000 mg/m(2) d1, q21d or q28d) or p.o. (400-600 mg/m(2) d1-14 or 21, q28d) for at least one therapy cycle were evaluable and were included in the study. RESULTS: With a median age of 70 years (range=36-92 years), predominantly elderly @entity1 received @entity21193 treatment. Most @entity1 presented serous histology (131, 52.8%) and advanced-stage FIGO III (122, 49%) or IV (55, 22%) disease. Median ECOG status was 1 (range=0-2), whereas cardiac co-morbidity was common (31%). @entity21193 was usually administered as second- (26%), third- (21%) or fourth-line (17%) therapy. Two hundred and one @entity1 received i.v. and 47 p.o. TREATMENT: The most common reason for dose modifications was due to hematological @entity137 (46%). The main reason for a therapy discontinuation was progressive disease (38.5%). Response was observed in 25.8% of @entity1 , disease stabilization in 28.6 % and progress in 45.6%. The median progression-free and overall survival was 196 and 405 days, respectively. CONCLUSION: In predominantly elderly and heavily pre-treated @entity1 with recurrent @entity43 , @entity21193 featured a clinical relevant efficacy and well-manageable, mostly hematological, @entity137 , which resulted in a positive therapeutic index.

@entity21193 in the Treatment of Advanced XXXX - Results of a German Multicenter Non-interventional Study.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'PATIENTS'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'ovarian cancer'] @entity21193 :: ('MESH:C018404', 'Chemical') :: ['treosulfan', 'Treosulfan'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']
@entity43 :: (MESH:D010051,Disease) :: ['Ovarian Cancer']
